HEAT
Hyperthermia European Adjuvant Trial*

A phase III, randomized, open multicenter clinical trial of adjuvant gemcitabine chemotherapy versus intensified therapy with gemcitabine, cisplatin and regional hyperthermia for patients with R0/R1 resected pancreatic cancer

Trial of the: ESHO (European Society for Hyperthermic Oncology)
AIO (Arbeitsgemeinschaft Internistische Onkologie)

For patients with:

- Complete (R0) or marginal (R1) resected pancreatic cancer
- Any ductal adenocarcinoma
- Age ≥ 18 years
- ECOG 0 - 2

N = 336

Randomization 1:1

Gemcitabine Standard
Gemcitabine 1000 mg/m²: days 1, 8 and 15, q4w

Primary Endpoint:
Disease-free Survival

Gemcitabine + Cisplatin + RHT
Gemcitabine 1000 mg/m²: days 1 and 15, q4w
Cisplatin 25 mg/m²: days 2, 3* and 16, 17*, q4w
Regional Hyperthermia (RHT) 60 min, 42°C: days 2, 3* and 16, 17*, q4w

* as an exception: for clinical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17

Follow up is performed every 3 months until death or lost to follow-up

Secondary Endpoints:

- Comparative overall survival (OS) of patients receiving gemcitabine or gemcitabine + cisplatin + regional hyperthermia
- Comparative DFS and OS of the subgroup of patients receiving at least 4 complete courses of gemcitabine or gemcitabine + cisplatin + regional hyperthermia

For more information, please visit www.pancreas-heat.de or call the HEAT Coordinators Trial Office: +49-89-7095 7776
e-mail to: heat@med.uni-muenchen.de

Supported by the European Society for Hyperthermic Oncology (ESHO)

EudraCT-Number: 2008-004802-14 AIO Number: AIO-PAK-0111
ClinicalTrials.gov Identifier: NCT 01077427

Version 02/2013